Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study

I. Selke Krulichová, GW. Selke, M. Bennie, M. Hajiebrahimi, F. Nyberg, J. Fürst, K. Garuolienė, E. Poluzzi, J. Slabý, CZ. Yahni, M. Altini, MP. Fantini, V. Kočí, S. McTaggart, C. Pontes, C. Reno, S. Rosa, MT. Pedrola, M. Udovič, B. Wettermark

. 2022 ; 31 (10) : 1046-1055. [pub] 20220718

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22024311

PURPOSE: The COVID-19 pandemic had an impact on health care, with disruption to routine clinical care. Our aim was to describe changes in prescription drugs dispensing in the primary and outpatient sectors during the first year of the pandemic across Europe. METHODS: We used routine administrative data on dispensed medicines in eight European countries (five whole countries, three represented by one region each) from January 2017 to March 2021 to compare the first year of the COVID-19 pandemic with the preceding 3 years. RESULTS: In the 10 therapeutic subgroups with the highest dispensed volumes across all countries/regions the relative changes between the COVID-19 period and the year before were mostly of a magnitude similar to changes between previous periods. However, for drugs for obstructive airway diseases the changes in the COVID-19 period were stronger in several countries/regions. In all countries/regions a decrease in dispensed DDDs of antibiotics for systemic use (from -39.4% in Romagna to -14.2% in Scotland) and nasal preparations (from -34.4% in Lithuania to -5.7% in Sweden) was observed. We observed a stockpiling effect in the total market in March 2020 in six countries/regions. In Czechia the observed increase was not significant and in Slovenia volumes increased only after the end of the first lockdown. We found an increase in average therapeutic quantity per pack dispensed, which, however, exceeded 5% only in Slovenia, Germany, and Czechia. CONCLUSIONS: The findings from this first European cross-national comparison show a substantial decrease in dispensed volumes of antibiotics for systemic use in all countries/regions. The results also indicate that the provision of medicines for common chronic conditions was mostly resilient to challenges faced during the pandemic. However, there were notable differences between the countries/regions for some therapeutic areas.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024311
003      
CZ-PrNML
005      
20221031100306.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pds.5509 $2 doi
035    __
$a (PubMed)35791700
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Selke Krulichová, Iva $u Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic $1 https://orcid.org/0000000268150780
245    10
$a Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study / $c I. Selke Krulichová, GW. Selke, M. Bennie, M. Hajiebrahimi, F. Nyberg, J. Fürst, K. Garuolienė, E. Poluzzi, J. Slabý, CZ. Yahni, M. Altini, MP. Fantini, V. Kočí, S. McTaggart, C. Pontes, C. Reno, S. Rosa, MT. Pedrola, M. Udovič, B. Wettermark
520    9_
$a PURPOSE: The COVID-19 pandemic had an impact on health care, with disruption to routine clinical care. Our aim was to describe changes in prescription drugs dispensing in the primary and outpatient sectors during the first year of the pandemic across Europe. METHODS: We used routine administrative data on dispensed medicines in eight European countries (five whole countries, three represented by one region each) from January 2017 to March 2021 to compare the first year of the COVID-19 pandemic with the preceding 3 years. RESULTS: In the 10 therapeutic subgroups with the highest dispensed volumes across all countries/regions the relative changes between the COVID-19 period and the year before were mostly of a magnitude similar to changes between previous periods. However, for drugs for obstructive airway diseases the changes in the COVID-19 period were stronger in several countries/regions. In all countries/regions a decrease in dispensed DDDs of antibiotics for systemic use (from -39.4% in Romagna to -14.2% in Scotland) and nasal preparations (from -34.4% in Lithuania to -5.7% in Sweden) was observed. We observed a stockpiling effect in the total market in March 2020 in six countries/regions. In Czechia the observed increase was not significant and in Slovenia volumes increased only after the end of the first lockdown. We found an increase in average therapeutic quantity per pack dispensed, which, however, exceeded 5% only in Slovenia, Germany, and Czechia. CONCLUSIONS: The findings from this first European cross-national comparison show a substantial decrease in dispensed volumes of antibiotics for systemic use in all countries/regions. The results also indicate that the provision of medicines for common chronic conditions was mostly resilient to challenges faced during the pandemic. However, there were notable differences between the countries/regions for some therapeutic areas.
650    _2
$a antibakteriální látky $7 D000900
650    12
$a COVID-19 $x epidemiologie $7 D000086382
650    _2
$a kontrola infekčních nemocí $7 D003140
650    _2
$a lékové předpisy $7 D011307
650    _2
$a lidé $7 D006801
650    _2
$a pandemie $7 D058873
650    _2
$a lékařská praxe - způsoby provádění $7 D010818
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Selke, Gisbert W $u Pharmaceuticals Information Systems and Analyses, AOK Research Institute (WIdO), Berlin, Germany $1 https://orcid.org/0000000296149875
700    1_
$a Bennie, Marion $u Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK $u Public Health and Intelligence, Public Health Scotland, Edinburgh, UK $1 https://orcid.org/000000024046629X
700    1_
$a Hajiebrahimi, Mohammadhossein $u Department of Pharmacy, Uppsala University, Uppsala, Sweden $1 https://orcid.org/0000000181184988
700    1_
$a Nyberg, Fredrik $u School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden $1 https://orcid.org/0000000308925668
700    1_
$a Fürst, Jurij $u Department of Medicinal Products, Health Insurance Institute of Slovenia, Ljubljana, Slovenia
700    1_
$a Garuolienė, Kristina $u Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania $1 https://orcid.org/0000000179100108
700    1_
$a Poluzzi, Elisabetta $u Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy $1 https://orcid.org/0000000272090426
700    1_
$a Slabý, Juraj $u Section of Pricing and Reimbursement Regulation, State Institute for Drug Control, Praha, Czech Republic
700    1_
$a Yahni, Corinne Zara $u Drug Department, Catalan Health Service, Barcelona, Spain $1 https://orcid.org/0000000268312233
700    1_
$a Altini, Mattia $u Healthcare Administration, Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy $1 https://orcid.org/000000021809184X
700    1_
$a Fantini, Maria Pia $u Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy $1 https://orcid.org/0000000232576552
700    1_
$a Kočí, Václav $u Section of Pricing and Reimbursement Regulation, State Institute for Drug Control, Praha, Czech Republic
700    1_
$a McTaggart, Stuart $u Public Health and Intelligence, Public Health Scotland, Edinburgh, UK $1 https://orcid.org/0000000160609019
700    1_
$a Pontes, Caridad $u Drug Department, Catalan Health Service, Barcelona, Spain $u Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000232746048
700    1_
$a Reno, Chiara $u Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy $1 https://orcid.org/0000000279332141
700    1_
$a Rosa, Simona $u Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy
700    1_
$a Pedrola, Marta Turu $u Drug Department, Catalan Health Service, Barcelona, Spain $1 https://orcid.org/0000000169573155
700    1_
$a Udovič, Mitja $u Department of Medicinal Products, Health Insurance Institute of Slovenia, Ljubljana, Slovenia
700    1_
$a Wettermark, Björn $u Department of Pharmacy, Uppsala University, Uppsala, Sweden $u Pharmacy Center, Faculty of Medicine, Vilnius University, Vilnius, Lithuania $1 https://orcid.org/0000000305312516
773    0_
$w MED00007447 $t Pharmacoepidemiology and drug safety $x 1099-1557 $g Roč. 31, č. 10 (2022), s. 1046-1055
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35791700 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100304 $b ABA008
999    __
$a ok $b bmc $g 1854183 $s 1175601
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 31 $c 10 $d 1046-1055 $e 20220718 $i 1099-1557 $m Pharmacoepidemiology and drug safety $n Pharmacoepidemiol Drug Saf $x MED00007447
LZP    __
$a Pubmed-20221017
Back

Find record

Citation metrics

Archiving options